drugset / Trial / NCT03037151
Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
Phase 4
Unknown
100 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Chulalongkorn University · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection with or without human immunodeficiency virus (HIV) infection.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elbasvir | Small molecule | 50 mg | — |
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 100 mg | — |
| Subject | RBV | Unknown | — | — |